Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -4.11% | 75.23 | 0.0% | $2385.15m | |
| NVAX | Novavax, Inc. | 8.28% | 170.19 | 99.2% | $1263.64m | |
| GILD | Gilead Sciences, Inc. | -2.37% | 69.20 | 1.0% | $527.29m | |
| AMGN | Amgen, Inc. | -0.97% | 241.24 | 1.3% | $510.65m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.53% | 632.01 | 2.5% | $463.54m | |
| SRNE | Sorrento Therapeutics, Inc. | 6.54% | 13.68 | 1.8% | $444.53m | |
| BNTX | BioNTech SE | -2.54% | 81.06 | 0.0% | $402.40m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.43% | 271.77 | 1.9% | $379.08m | |
| VXRT | Vaxart, Inc. | 10.06% | 9.79 | 0.0% | $329.51m | |
| ILMN | Illumina, Inc. | 2.52% | 403.58 | 3.5% | $327.99m | |
| BIIB | Biogen, Inc. | -0.08% | 275.87 | 1.6% | $326.68m | |
| IBIO | iBio, Inc. | 1.03% | 4.44 | 1.8% | $184.72m | |
| EBS | Emergent BioSolutions, Inc. | 8.30% | 132.81 | 6.4% | $175.25m | |
| SGEN | Seattle Genetics, Inc. | -1.12% | 163.23 | 6.1% | $173.16m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -2.18% | 102.93 | 2.0% | $171.16m |
Company Profile
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.